---
document_datetime: 2024-07-23 14:33:47
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/biktarvy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: biktarvy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 10.4976492
conversion_datetime: 2025-12-28 00:09:16.765442
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Biktarvy

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                       |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0059              | Update of sections 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC in order to update information on pregnancy and dosing recommendations with polyvalent cation-containing products for pregnant individuals based on final results from study GS-US- 380-5310; A Phase 1b, Open-label study to Evaluate | 27/06/2024                          |                                             | SmPC, Labelling and PL           | A clinical study was conducted in HIV-1 infected virologically suppressed pregnant adults receiving Biktarvy from the second or third trimester through postpartum. All 32 adult participants who completed the study maintained viral suppression during pregnancy, at delivery, and through Week 18 postpartum. All 29 neonate participants |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | the Pharmacokinetics (PK), Safety and Efficacy of B/F/TAF in HIV-1 infected, Virologically Suppressed, Pregnant Women in their Second and Third Trimesters; study GS-US-380-3909 and the Antiretroviral Pregnancy Registry. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                        |            |     | had negative/nondetectable HIV-1 PCR results at birth and/or 4 to 8 weeks of age. Exposures of bictegravir, emtricitabine and tenofovir alafenamide were lower during pregnancy. Therefore, Biktarvy may be used during pregnancy if the potential benefit justifies the potential risk to the foetus. Moreover, viral load should all the more be monitored closely in accordance with established treatment guidelines. There were no new safety findings compared to the known safety profile of Biktarvy in HIV-1 infected adults. In pregnant individuals dosage adjustments are recommended for co-administration of polyvalent cation- containing antacids, oral medications or supplements. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1722/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 04/04/2024 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0058   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                       | 04/03/2024 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| WS/2540   | for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                                                                                                                                        | 14/12/2023   | n/a        |             | This was an application variation   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------|
| IG/1626/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 23/06/2023   | n/a        |             | batch control/testing               |
| IB/0053   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 28/04/2023   | 19/04/2024 | SmPC and PL |                                     |
| IA/0055   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/04/2023   | n/a        |             |                                     |

<div style=\"page-break-after: always\"></div>

|                     | the product information                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                                                                                                                                                                                                                                                                        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0054             | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                                                      | 24/04/2023 | n/a        |                        |                                                                                                                                                                                                                                                                        |
| R/0052              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                   | 10/11/2022 | 10/01/2023 | SmPC and PL            | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Biktarvy in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10695 /202202 | Periodic Safety Update EU Single assessment - bictegravir / emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                         | 15/09/2022 | 21/11/2022 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10695/202202.                                                                                                                             |
| X/0040/G            | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                              | 15/09/2022 | 21/11/2022 | SmPC, Labelling and PL | Please refer to scientific discussion Biktarvy-H-C-004449-X- 0040-G.                                                                                                                                                                                                   |
| WS/2315/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation | 10/11/2022 | n/a        |                        |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0050/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                            | 08/08/2022 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0049   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                      | 22/06/2022 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0047   | Update of sections 4.8 and 5.1 of the SmPC in order to include efficacy and safety data for antiretroviral therapy (ART)-naive adults based on final results from interventional studies GS-US-380-1489 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS- 9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir /Dolutegravir /Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults) and GS-US-380-1490 (A Phase 3, Randomized, Double- Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus | 10/06/2022 | 21/11/2022 | SmPC | Final efficacy and safety data from studies GS-US-380- 1489 and GS-US-380-1490 in ART-naive adults through 96 weeks of open-label treatment on Biktarvy (BVY) following 144 weeks of a double-blinded phase (BVY vs ABC/DTG/3TC in study GS-US-380-1489 or BVY vs DTG+F/TAF in study GS-US-380-1490) were submitted. These 5-years BVY data for subjects treated with BVY at baseline (ART-naïve subjects) and 2-years BVY data for subjects who switched from ABC/DTG/3TC or from DTG+F/TAF to BVY at the end of the double-blinded phase (i.e. virologically-suppressed subjects with a DTG-based first line regimen) demonstrate that, overall, BVY is |

<div style=\"page-break-after: always\"></div>

|                     | Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults). In addition, the MAH took this opportunity to introduce some minor administrative updates. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | associated with a long-term efficacy, without resistance emerging concern. Of note, the population of this study (and therefore the current therapeutic indication of BVY) was mainly without INSTI, FTC and TAF resistance, thus these efficacy data of BVY may not be extrapolated for the treatment of subjects who already experienced virological failure. No new safety concern emerged since the previous assessment of the Week 144 data: the long-term safety data of BVY are consistent with its known safety profile, notably as regards the hepatic and renal effects. Sections 4.8 and 5.1 of the SmPC were updated to reflect the final results from GS-US-380-1489 and GS-US-380- 1490 efficacy and safety studies. For more information, please refer to the Summary of   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10695 /202108 | Periodic Safety Update EU Single assessment - bictegravir / emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                            | 10/03/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0046             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                       | 20/12/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0043/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                | 14/12/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products              |            |            |             |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IG/1456             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient           | 08/11/2021 | n/a        |             |                                   |
| PSUSA/10695 /202102 | Periodic Safety Update EU Single assessment - bictegravir / emtricitabine / tenofovir alafenamide                                                                                                                                                      | 02/09/2021 | n/a        |             | PRAC Recommendation - maintenance |
| IAIN/0042/G         | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 01/09/2021 | n/a        |             |                                   |
| IG/1412             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient           | 28/07/2021 | n/a        |             |                                   |
| WS/2030             | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                   | 20/05/2021 | 22/10/2021 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | Regulation (EC) No 1234/2008. To update section 4.4 of the SmPC and section 2 of the PL with information regarding nephrotoxicity, in alignment with the outcome of procedure EMEA/H/C/PSUSA/00010575/201911 already approved for Vemlidy. In addition, the marketing authorisation holder has taken the opportunity to introduce minor editorial changes for Biktarvy and to align the PI of all four products to the latest QRD template (v. 10.2). C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation   |            |            |                        | Commission   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------|
| IG/1399   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                           | 18/05/2021 | n/a        |                        |              |
| IB/0036/G | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid                                                                                                                                                                                                                                                      | 15/04/2021 | 22/10/2021 | SmPC, Labelling and PL |              |

<div style=\"page-break-after: always\"></div>

|                     | pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10695 /202008 | Periodic Safety Update EU Single assessment - bictegravir / emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                                                                           | 11/03/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10695 /202002 | Periodic Safety Update EU Single assessment - bictegravir / emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                                                                           | 17/09/2020 | 18/11/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10695/202002.                                                                                                                                                                                                                                                                      |
| II/0034             | Update of section 4.8 of the SmPC in order to add the Stevens-Johnson Syndrome (SJS) to the list of adverse drug reactions (ADRs) with frequency 'rare' based on an internal cumulative safety review performed by the company and prompted by a spontaneous case report of a HIV patient who experienced SJS during treatment with Biktavry. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 29/10/2020 | 22/10/2021 | SmPC and PL | SmPC new text: The risk of Stevens-Johnson Syndrome (SJS) is added to the list of Undesirable effects of Biktarvy with a frequency of rare. This adverse reaction was identified through post- marketing surveillance for Biktarvy. For more information, please refer to the Summary of Product Characteristics.                                                                                               |
| II/0029             | Update of sections 4.2, 4.4, 4.8 and 5.2 of the SmPC in order to update the efficacy and safety data in haemodialysis patients population based on week 48 interim results from study GS-US-292-182, 'A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis'. The Package Leaflet is updated accordingly. In addition,                                               | 17/09/2020 | 28/10/2020 | SmPC and PL | Based on week 48 interim results from study GS-US-292- 182, no dose adjustment of Biktarvy is required in adult HIV-1 patients with end stage renal disease (estimated creatinine clearance < 15 mL/minute) who are receiving chronic haemodialysis. However, Biktarvy should generally be avoided and only be used in these patients if the potential benefits are considered to outweigh the potential risks. |

<div style=\"page-break-after: always\"></div>

|         | linguistic amendments and editorial changes to the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |      | Biktarvy after completion of haemodialysis treatment. In addition, initiation of Biktarvy should be avoided in patients with estimated creatinine clearance ≥15 mL/min and < 30 mL/min, or < 15 mL/min who are not receiving chronic haemodialysis, as the safety of Biktarvy has not been established in these populations. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1278 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 27/08/2020 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0032 | Update of sections 4.2 and 4.8 of the SmPC in order to update the efficacy and safety data in HIV-1 infected subjects aged ≥ 65 years based on week 48 interim results from study GS-US-380-4449, 'A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate Containing Regimen to Fixed-Dose Combination of Bictegravir /Emtricitabine/Tenofovir Alafenamide in Elderly, Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 65 Years'. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 23/07/2020 | 28/10/2020 | SmPC | The marketing authorisation holder (MAH) presented results from a study (GS-US-380-4449) to evaluate the potential benefits of switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or a tenofovir disoproxil fumarate (TDF)- containing regimen to Biktarvy in subjects aged ≥65 years. No efficacy or safety concerns were raised on this sub- population during the MA procedure for Biktarvy but the proportion of patients from this specific population was limited. The dedicated study GS-US-380-4449 in patients > 65 y/o submitted for this current application is mainly relevant to substantiate the safety in this sub-population. Based on this, the product information has been updated to reflect the efficacy and safety data in HIV-1 infected subjects aged ≥ 65 years based on this week 48 interim results from study GS-US-380-4449, showing a similar |

<div style=\"page-break-after: always\"></div>

|                     | data                                                                                                                                                                                                                                         |            |            |                   | safety profile of Biktarvy in these subjects to that in younger adults. No new safety signal has emerged. In addition, the MAH took the opportunity to make some minor editorial changes to the PI, in section 5.1 of the SmPC. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1745             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 28/05/2020 | 28/10/2020 | PL                |                                                                                                                                                                                                                                                                                                                 |
| IG/1236             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 04/05/2020 | n/a        |                   |                                                                                                                                                                                                                                                                                                                 |
| II/0027             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                            | 13/02/2020 | 28/10/2020 | SmPC and Annex II |                                                                                                                                                                                                                                                                                                                 |
| PSUSA/10695 /201908 | Periodic Safety Update EU Single assessment - bictegravir / emtricitabine / tenofovir alafenamide                                                                                                                                            | 13/02/2020 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                               |
| WS/1746             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                | 06/02/2020 | n/a        |                   |                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                              |            |            |                       |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| IB/0025             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                           | 04/12/2019 | 28/10/2020 | SmPC                  |                                   |
| IAIN/0024           | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                    | 22/10/2019 | n/a        |                       |                                   |
| PSUSA/10695 /201902 | Periodic Safety Update EU Single assessment - bictegravir / emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                   | 05/09/2019 | n/a        |                       | PRAC Recommendation - maintenance |
| IA/0022             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                          | 30/08/2019 | n/a        |                       |                                   |
| II/0008/G           | This was an application for a group of variations. Update of section 4.5 of the SmPC in order to remove the recommendation for caution when methadone is co-administered with Biktarvy, based on final results from study AD-141-2321, an in vitro assessment of human Cytochrome P450 inhibition potential of GS-943389 (the sulfate metabolite, M20, of bictegravir). The Package Leaflet is updated accordingly. | 27/06/2019 | 21/10/2019 | SmPC, Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|         | In addition, the Marketing authorisation holder (MAH) took the opportunity to remove reference to boceprevir in sections 4.4 and 4.5 of the SmPC and in the Package Leaflet as it is no longer available in the EU; as well as to introduce some minor editorial corrections throughout the SmPC and the Package Leaflet. Submission of the final report from study AD-141- 2322, an in vitro assessment of the inhibition potential of GS-943389 against human P-gp and BCRP transporters. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   |            |     | of   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| IB/0021 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 20/06/2019 | n/a |      |
| IA/0020 | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 24/05/2019 | n/a |      |
| IA/0019 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 24/05/2019 | n/a |      |

<div style=\"page-break-after: always\"></div>

|         | manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1566 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC following a safety review by the MAH assessing the clinical evidence of a causal association between tenofovir alafenamide- containing products and two adverse events, angioedema and urticaria. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor linguistic amendments and editorial changes to the Odefsey and Vemlidy products information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 02/05/2019 | 21/10/2019 | SmPC, Annex II, Labelling and PL | Based on post-marketing surveillance data, there is sufficient evidence to consider that a causal association between tenofovir alafenamide-containing products and two adverse events, angioedema and urticaria, with the frequency uncommon. The Product information is updated accordingly.                                                                                                                                                                                                                                         |
| II/0011 | Update of sections 4.8 and 5.1 of the SmPC in order to update the efficacy and safety information based on the pooling of 96-week data from two randomized, double-blind, active controlled studies GS-US-380-1489 and GS-US-380-1490 in HIV-1 infected, antiretroviral treatment-naïve adults receiving Biktarvy compared with each of the comparator treatment groups (i.e. pooled Biktarvy (BVY) vs abacavir /dolutegravir /lamivudine and pooled BVY vs dolutegravir + emtricitabine/tenofovir alafenamide).                                                                                                                                                                                     | 26/04/2019 | 21/10/2019 | SmPC and PL                      | The week 96 analysis of the ongoing, randomized, double- blind, active controlled studies GS-US-380-1489 and GS- US-380-1490 in HIV-1 infected, treatment-naïve adults, is in line with the week 48 data, and similar conclusions could be drawn. Biktarvy is non-inferior in achieving HIV 1 RNA < 50 copies/mL when compared to abacavir/dolutegravir/lamivudine and to dolutegravir+emtricitabine/tenofovir alafenamide, respectively. The trend in favour of the dolutegravir comparator arm in subjects with baseline HIV-1 RNA > |

<div style=\"page-break-after: always\"></div>

|             | In addition the Marketing authorisation holder (MAH) took the opportunity to introduce some minor linguistic amendments in the SmPC and the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | 100,000 copies/mL or CD4 cell count < 200 cells/μl already identified at week 48 is still apparent at week 96. Those subgroup analyses have been updated with 96-week data. No subject in any group developed treatment-emergent resistance to study drugs. The safety profile of Biktarvy at Week 96 did not differ from that at Week 48, and overall remains similar to dolutegravir+emtricitabine/tenofovir alafenamide. No new safety findings have been identified. Based on 96-week data sections 4.8 and 5.1 of the SmPC have been updated accordingly.   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014     | B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                                                                                                                                | 13/03/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0013     | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                             | 13/03/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0016   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                    | 19/02/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0015     | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                              | 15/02/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10695 | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                    | 14/02/2019 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| /201808   | bictegravir / emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------|
| IA/0012   | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                         | 30/01/2019 | n/a |                               |
| IB/0010   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                       | 30/01/2019 | n/a |                               |
| IB/0003/G | This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                | 30/12/2018 | n/a |                               |
| IA/0009/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting | 05/12/2018 | n/a | material/intermediate/reagent |

<div style=\"page-break-after: always\"></div>

|           | specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/1466/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 29/11/2018 | n/a |
| IG/1001   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/11/2018 | n/a |

<div style=\"page-break-after: always\"></div>

| IB/0004/G   | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   | 23/11/2018   | n/a        |                        |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|
| IG/0995     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                            | 24/10/2018   | 21/10/2019 | SmPC                   |
| T/0001      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/07/2018   | 23/08/2018 | SmPC, Labelling and PL |